Cargando…
Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review
Tyrosine kinase inhibitors (TKIs) are the key agents for treating CML and BCR–ABL(+) B‐ALL. Dasatinib is a potent second‐generation TKI. Here, we have discussed the case of a 51‐year‐old gentleman diagnosed with B‐myeloid mixed‐phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR–ABL1p210, in com...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175909/ https://www.ncbi.nlm.nih.gov/pubmed/35844702 http://dx.doi.org/10.1002/jha2.226 |